In pursuit of stability enhancement of a prostate cancer targeting antibody derived from a transgenic animal platform

Venkataramani, S., Ernst, R., Derebe, M.G., et al.

Scientific Reports 2020, vol: 10 doi: 10.1038/s41598-020-66636-z

Abstract

Accelerated timelines necessitate the discovery of fully human antibodies as biotherapeutics using transgenic animals with a notion that such mAbs bypass humanization. A transgenic animal derived mAb (PCa75) targeted against a prostate cancer antigen had several ‘unusual residues’ (rare somatic hypermutations, rSHM, with positional frequency of <1%) that resulted in compromised biophysical properties (Tm = 61 °C and intrinsic stability ΔGu = 24.3 kJ/mol) and a sub-optimal immunogenicity profile. In our quest for quality medicine, we pursued antibody engineering strategies to enhance the stability of PCa75. PCa62, an engineered variant of PCa75, retained function while significantly improving the drug-like attributes of the molecule (Tm = 75 °C and intrinsic stability ΔGu = 63.5 kJ/mol). rSHM is rather prevalent, 18 out the 21 approved transgenic animal-derived antibodies have at least one ‘unusual residue’. Thus, engineering of rSHM remains critical to enhance the stability and minimize immunogenicity risk of biotherapeutics.

View Publication
 

Topics: Prometheus – nanoDSF,  Publications

 

 

 

Previous Video
The new gold standard in biologic characterization – Develop your biologics faster and better with Prometheus
The new gold standard in biologic characterization – Develop your biologics faster and better with Prometheus

Development of therapeutic antibodies is a long and costly process. One key indicator of whether biologic c...

Up next
How to export your data and set export templates in PR.Stability Analysis software
How to export your data and set export templates in PR.Stability Analysis software

As you become an expert in analysis with your Prometheus data, you will start to streamline your analysis p...

Have a question about Prometheus?

Contact Specialist
×

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!